Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.32 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8097087 | 0.81 | GABRA1 (0.41) | P2RX7YTHDC1 | |
| SCHEMBL29149335 | 0.81 | P2RX7 (0.34) | P2RX7YTHDC1 | |
| SCHEMBL6299275 | 0.78 | P2RX7 (0.35) | P2RX7YTHDC1 | |
| SCHEMBL395017 | 0.76 | GABRA1 (0.44) | — | |
| SCHEMBL2306517 | 0.76 | TSHR (0.35) | P2RX7YTHDC1 | |
| SCHEMBL6957919 | 0.76 | TSHR (0.35) | — | |
| SCHEMBL30139122 | 0.76 | ALDH1A1 (0.38) | P2RX7YTHDC1 | |
| SCHEMBL3518623 | 0.76 | ALDH1A1 (0.38) | P2RX7YTHDC1 | |
| SCHEMBL16266548 | 0.76 | PNMT (0.44) | P2RX7 | |
| SCHEMBL1178546 | 0.76 | APOBEC3G (0.43) | P2RX7YTHDC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105143207-B | Substituted pyridine and substituted pyrazine compounds as PDE4 inhibitors | 达特神经科学(开曼)有限公司 | 2018-04-24 | — | — | CN | claimed |
| CN-108299400-A | Substituted pyridine as PDE4 inhibitor and substituted pyrazine compound | 达特神经科学(开曼)有限公司 | 2018-07-20 | — | — | CN | disclosed |
| CN-105143207-B | Substituted pyridine and substituted pyrazine compounds as PDE4 inhibitors | 达特神经科学(开曼)有限公司 | 2018-04-24 | — | — | CN | disclosed |
| US-9635857-B2 | Tetrazolinone compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-05-02 | — | — | US | disclosed |
| US-20160235065-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-08-18 | — | — | US | disclosed |
| EP-1329160-A2 | 4-ACYLAMINOPYRAZOLE DERIVATIVES | Sankyo Company, Limited (JP) | 2003-07-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160235065-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | MRPS17, TAOK1, TAOK3 | P2RX7 695/4885YTHDC1 3567/4885PRKCQ 3881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.